What is Bioventix PLC's (BVXP.L) StockRank?

MoatMap's StockRank for Bioventix PLC (BVXP.L) is 96/100, with a Strong Buy signal. This is a composite score combining Quality (84), Value (48), and Momentum (58) factor ranks across MoatMap's 20,000+ stock universe.

Does Bioventix PLC have an economic moat?

Bioventix PLC (BVXP.L) has a Quality factor score of 84/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Bioventix PLC a buy, hold, or sell?

MoatMap's current signal for Bioventix PLC (BVXP.L) is Strong Buy, based on a StockRank of 96/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Bioventix PLC in?

Bioventix PLC (BVXP.L) operates in the Healthcare sector, specifically the Biotechnology industry (United Kingdom).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

BVXP.L

STRONG BUYFLAG

Bioventix PLC · Healthcare · United Kingdom · $117M · Avg Vol: $212K/d

StockRank

P/E (TTM)

11.5x

ROE

66.6%

D/E

—

Dividend %

0.1%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Bioventix is an incredibly high-quality business (Q-score of 85) producing monoclonal antibodies for clinical diagnostics with near-monopoly moats and exceptional ROIC. However, its micro-cap size ($87M) limits institutional liquidity, and it is not a direct play on the CDMO manufacturing bottleneck.

COMPANY DESCRIPTION

Bioventix PLC develops and manufactures high-affinity sheep monoclonal antibodies (SMAs) for use in clinical diagnostics. The company possesses a powerful economic moat through proprietary cell lines that produce antibodies integrated into global, long-term diagnostic platforms. It is a high-margin, cash-generative biotechnology company with a highly defensive royalty-based business model.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	16M	17M	18M	18M	3.8%
EPS	1.98	2.16	208.25	1.95	-0.5%
Shares	5M	5M	5M	5M	+0.3%
Debt	2M	2M	2M	2M	0.4%
Equity	16M	16M	16M	16M	-0.8%
Op CF	10M	10M	11M	9M	-2.4%
Inv CF	-9,333	121,512	249,782	232,470	—
Fin CF	-11M	-11M	-11M	-11M	—

PRICE (1M)+7.4%

SMA 50SMA 200

$24.50

RSI (14)

64.4

52W High

$40.51

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

87.2%99.7

ROE

66.6%98.1

GP/Assets

89.3%96.5

Op. Margin

76.6%99.5

FCF/Assets

50.8%98.4

Piotroski

—83.4

Int. Cover

—N/A

D/E Ratio

—N/A

Current Ratio

6.12x76.6

Value

P/E (TTM)

11.5x85.0

EV/EBITDA

8.1x48.5

P/FCF

9.8x75.4

P/B

7.7x14.8

P/S

6.8x33.0

Div Yield

0.1%4.2

Momentum

52W High %

60%41.3

RS 6M

1%77.5

SMA 50/200

0.91x37.4

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+12616%99.8

Q Growth

-4%37.1

FUNDAMENTALS

Market Cap

$117M

P/E (Forward)

0.1x

Gross Margin

92.4%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BVXP.L are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
BVXP.L	Bioventix PLC(you)	$117M	96	STRONG BUY
AREC.L	Arecor Therapeutics plc	$34M	59	HOLD
POLB.L	Poolbeg Pharma PLC	$56M	39	HOLD
SCLP.L	Scancell Holdings plc	$333M	37	HOLD
4BB.L	4basebio PLC	$110M	5	STRONG SELL
HEMO.L	Hemogenyx Pharmaceuticals Plc	$63M	14	STRONG SELL
GNS.L	Genus plc	$2.1B	58	HOLD
IXI.L	IXICO plc	$25M	29	SELL
SBTX.L	SkinBioTherapeutics plc	$34M	21	SELL
SAR.L	Sareum Holdings plc	$47M	14	STRONG SELL

Peer medians: ROE -1.8% · P/E 27.0x · Gross margin 50.8%

Bioventix PLC (BVXP.L) — Stock Score Summary

Bioventix PLC (BVXP.L) has a MoatMap StockRank of 96/100 based on Quality (84/100), Value (48/100), and Momentum (58/100) factor scores. The current signal is STRONG BUY. Bioventix is an incredibly high-quality business (Q-score of 85) producing monoclonal antibodies for clinical diagnostics with near-monopoly moats and exceptional ROIC. However, its micro-cap size ($87M) limits institutional liquidity, and it is not a direct play on the CDMO manufacturing bottleneck.

Key Financial Metrics

Price	$24.50
Market Cap	$117M
P/E (TTM)	11.52
P/E (Forward)	0.09
Price/Book	7.69
Return on Equity	66.6%
Return on Invested Capital	87.2%
Gross Margin	92.4%
Operating Margin	76.6%
Revenue Growth	-8.5%
Dividend Yield	0.1%
Free Cash Flow	$12M

Bioventix PLC operates in the Biotechnology industry, part of the Healthcare sector (United Kingdom).

Frequently Asked Questions

What is Bioventix PLC’s (BVXP.L) StockRank?: MoatMap’s StockRank for Bioventix PLC (BVXP.L) is 96/100, with a Strong Buy signal. It is a composite of Quality (84), Value (48), and Momentum (58) factor ranks across MoatMap’s 20,000+ stock universe.
Does Bioventix PLC have an economic moat?: Bioventix PLC (BVXP.L) has a Quality factor score of 84/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Bioventix PLC a buy, hold, or sell?: MoatMap’s current signal for Bioventix PLC (BVXP.L) is Strong Buy, based on a StockRank of 96/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Bioventix PLC in?: Bioventix PLC (BVXP.L) operates in the Healthcare sector, specifically the Biotechnology industry (United Kingdom).